Fed Governor Cook sues Trump over firing attempt
CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a company at the forefront of applying artificial intelligence in healthcare to advance precision medicine, has announced the acquisition of Deep 6 AI. With a market capitalization of $7.8 billion and impressive revenue growth of 30% over the last twelve months, Tempus continues to expand its footprint. This move is set to enhance Tempus’s capabilities in supporting healthcare organizations and life sciences companies with AI-driven research platforms. According to InvestingPro data, the company maintains a healthy liquidity position with a current ratio of 2.29.
Deep 6 AI’s technology focuses on streamlining clinical trials by leveraging AI to match patients with trials using real-time data from electronic medical records. This acquisition is poised to expand Tempus’s existing network, which already encompasses a vast library of multimodal data and an operating system designed to make that data useful for healthcare providers. The market has responded cautiously to this strategic move, with the stock declining 14% over the past week. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks.
Eric Lefkofsky, Founder and CEO of Tempus, stated that Deep 6 AI’s robust integration infrastructure will complement Tempus’s efforts to optimize patient care. The acquisition is expected to broaden Tempus’s reach by adding more providers to its platform and enhancing the deployment of applications like Next, which assists physicians in addressing care gaps, and TIME, which aids patients in finding clinical trials.
Tempus is known for its AI-enabled precision medicine solutions that assist physicians in providing personalized patient care. The company also supports the discovery, development, and delivery of therapeutics, aiming to improve treatments for future patients based on the data gathered from previous cases.
While the press release includes forward-looking statements about the potential benefits of the acquisition and Tempus’s future operations, these statements are subject to various risks and uncertainties. Analysts project continued losses for the company in the coming year, with an EPS forecast of -$0.52. As with any business development, the integration of Deep 6 AI into Tempus’s operations and the realization of expected benefits will be closely watched by investors and industry observers. InvestingPro subscribers can access additional financial health metrics and 7 more exclusive ProTips to make informed investment decisions.
This news is based on a press release statement and provides a glimpse into Tempus’s strategic direction as the company continues to expand its role in the healthcare technology sector.
In other recent news, Tempus AI Inc has reported a strong fourth-quarter revenue growth of 35.8% year-over-year, reaching $700 million. Despite this robust performance, the company’s earnings per share (EPS) came in at -0.18. Tempus AI has revised its 2025 revenue guidance to approximately $1.24 billion, slightly above the previous estimate of $1.23 billion. The company completed the acquisition of Ambry Genetics, which is expected to contribute to Tempus AI’s projected growth in core revenue by over 30% year-over-year.
Analyst reactions to these developments have been mixed. Stifel analysts maintained a Hold rating on Tempus AI shares, with a $65 price target, citing fair market valuation compared to peers. On the other hand, JPMorgan downgraded the stock from Overweight to Neutral but raised the price target to $55, acknowledging the company’s sustainable Data & Service Revenue and increasing profitability. The company also launched the Olivia AI personal health app, expanding its product offerings in the healthcare sector.
Tempus AI’s management remains optimistic about the company’s growth trajectory, with expectations for adjusted EBITDA of $5 million for the current year. However, the company faces challenges, such as a projected slowdown in Ambry Genetics’ growth and questions about total contract value for data services. Despite these hurdles, Tempus AI continues to focus on innovation and strategic partnerships to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.